Vaccinex, which is developing antibody therapies to combat cancer and neurological diseases, filed on Monday with the SEC to raise up to $46 million in an initial public offering.
The Rochester, NY-based company was founded in 2001 and plans to list on the Nasdaq under the symbol VCNX. Oppenheimer & Co. and BTIG are the joint bookrunners on the deal. No pricing terms were disclosed.
